Requests that the FDA declare that the drug product, Lenalidomide Oral Solution 5 mg/mL is suitable for consideration in an Abbreviated New Drug Application. | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

Open for Comments

FDA-2026-P-7177

Requests that the FDA declare that the drug product, Lenalidomide Oral Solution 5 mg/mL is suitable for consideration in an Abbreviated New Drug Application.

Documents

Comments

Key Dates

Comment Period OpensJun 29, 2026

Documents

Type	Title	Posted	Comments	Status
Other	Completeness Assessment Correspondence to Lachman Consultant Services, Inc.	Jul 16, 2026	--

Keywords

CDER

Suitability Petition

Lachman Consultant Services Inc

declare that the drug product

Lenalidomide Oral Solution 5 mg mL

is suitable for consideration

in an Abbreviated New Drug Application

OPEN

Data from Regulations.gov